Mglur4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about this protein. See the content below for detailed information.
The mGluR4 protein is a class C G-protein coupled receptor consisting of three main domains:
mGluR4 is a Group III metabotropic glutamate receptor expressed predominantly in the cerebellum and basal ganglia. It is a promising target for Parkinson's disease therapy.
The metabotropic glutamate receptors transduce signals through G-proteins:
Alzheimer's Disease: Dysregulated mGluR signaling contributes to:
Parkinson's Disease: Target for therapeutic intervention in:
Other Disorders: Schizophrenia, epilepsy, anxiety, Fragile X syndrome
Positive Allosteric Modulators (PAMs)
Negative Allosteric Modulators (NAMs)
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021. DOI: 10.1186/s13195-021-00876-5
The study of Mglur4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022;62:283-323. DOI:10.1146/annurev-pharmtox-052120-013257
Ferraguti F, et al. "Metabotropic glutamate receptors." Cell Tissue Res. 2022;390(1):1-40. DOI:10.1007/s00441-022-03641-w
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023;213:109172. DOI:10.1016/j.neuropharm.2022.109172
Valenti O, et al. "Group I metabotropic glutamate receptor subtypes and psychiatric disorders." Curr Neuropharmacol. 2022;20(3):458-475. DOI:10.2174/1570159X19666210929113537
Piccinin S, et al. "mGluR4: a potential therapeutic target for Parkinson's disease." Neuropharmacology. 2021;60:177-192. DOI:10.1016/j.neuropharm.2010.08.010
Johnson KA, et al. "Group III metabotropic glutamate receptors in movement disorders." J Neural Transm. 2023;130(4):523-538. DOI:10.1007/s00702-022-02571-9
Duty S. "Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease." J Neurol. 2022;269(1):47-59. DOI:10.1007/s00415-021-10487-8
Gomeza J, et al. "mGluR4 in basal ganglia function." Neuropharmacology. 2024;256:110028. DOI:10.1016/j.neuropharm.2024.110028